Poseida Therapeutics PSTX

$ 2.72 0.37%

Quarterly report 2024-Q3
added 11-07-2024

Poseida Therapeutics Balance Sheet 2011-2024 | PSTX

Annual Balance Sheet Poseida Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	20.1 M	-17.3 M	-171 M	-51.8 M	-58.6 M	-11.3 M	-5.92 M	-	-	-	-	-	-
Long Term Debt	58.6 M	58.2 M	29.4 M	29.1 M	26.1 M	19.1 M	8.6 M	-	-	-	-	-	-
Long Term Debt Current	5.95 M	5.87 M	6.34 M	4.81 M	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	79.5 M	275 M	109 M	51.8 M	-	-	-	-	-	-
Total Current Liabilities	71.3 M	53.9 M	43.3 M	30 M	-	-	-	-	-	-	-	-	-
Total Liabilities	170 M	164 M	113 M	110 M	297 M	122 M	59 M	-	-	-	-	-	-
Deferred Revenue	31 M	19.7 M	4.5 M	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-594 M	-471 M	-407 M	-282 M	-152 M	-65.7 M	-21.3 M	-	-	-	-	-	-
Total Assets	274 M	352 M	269 M	371 M	147 M	45.1 M	25.5 M	-	-	-	-	-	-
Cash and Cash Equivalents	44.5 M	81.4 M	206 M	84 M	-	-	-	-	-	-	-	-	-
Book Value	104 M	188 M	156 M	262 M	-150 M	-76.7 M	-33.5 M	-	-	-	-	-	-
Total Shareholders Equity	104 M	188 M	156 M	262 M	-150 M	-	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Poseida Therapeutics

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	58.9 M	58.8 M	58.7 M	58.6 M	58.5 M	58.4 M	58.3 M	58.2 M	58.2 M	58.1 M	58 M	29.4 M	29.3 M	29.3 M	26.2 M	29.1 M	29.1 M	29.1 M	29.1 M	26.1 M	26.1 M	26.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	206 M	238 M	178 M	170 M	179 M	146 M	156 M	164 M	164 M	140 M	144 M	113 M	112 M	113 M	106 M	110 M	110 M	110 M	110 M	74.3 M	74.3 M	74.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	37.3 M	63.3 M	49.8 M	31 M	44.8 M	20.2 M	20.1 M	19.7 M	16.7 M	1.05 M	3.36 M	4.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-630 M	-650 M	-619 M	-594 M	-569 M	-537 M	-510 M	-471 M	-438 M	-508 M	-465 M	-407 M	-408 M	-366 M	-320 M	-282 M	-282 M	-282 M	-282 M	-152 M	-152 M	-152 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	294 M	299 M	263 M	274 M	302 M	281 M	314 M	352 M	380 M	205 M	248 M	269 M	262 M	299 M	333 M	371 M	371 M	371 M	371 M	147 M	147 M	147 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	49.3 M	30.5 M	53.3 M	44.5 M	25.5 M	49.9 M	40.1 M	81.4 M	165 M	63 M	183 M	206 M	198 M	200 M	170 M	84 M	84 M	84 M	84 M	87.8 M	87.8 M	87.8 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	87.2 M	60.8 M	84.6 M	104 M	124 M	135 M	158 M	188 M	216 M	65.8 M	104 M	156 M	150 M	187 M	227 M	262 M	262 M	262 M	262 M	72.7 M	72.7 M	72.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	87.2 M	60.8 M	84.6 M	104 M	124 M	135 M	158 M	188 M	216 M	65.8 M	104 M	156 M	150 M	187 M	227 M	262 M	262 M	262 M	262 M	-150 M	-150 M	-150 M	-89.6 M	-76.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency